Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 17;8(1):4.
doi: 10.1038/s41421-022-00375-5.

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination

Xiaoqi Yu #  1 , Dong Wei #  1 , Wenxin Xu #  1 , Yulong Li  1 , Xinxin Li  1 , Xinxin Zhang  2   3 , Jieming Qu  4   5   6 , Zhitao Yang  7 , Erzhen Chen  8
Affiliations

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination

Xiaoqi Yu et al. Cell Discov. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Anti-SARS-CoV-2-specific antibody and neutralizing antibody responses in serum samples of the 292 participants.
a The specific antibody levels against SARS-CoV-2 at different time points are shown. The horizontal dashed line represents the lower limit of detection (LLD) of 1. Results below the LLD were set to 0.5 times the LLD. Data points shown on the bar graph represent individual titers. Error bars indicate median and interquartile range (IQR). b Results of 50% pseudovirus neutralization titer (pVNT50) against the WT strain and the Omicron variant at the time points are shown. The horizontal dashed line represents the lower limit of detection (LLD) of 4. Results below the LLD were set to 0.5 times the LLD. Data points shown on the bar graph represent individual titers. Error bars represent the geometric mean with the 95% confidence interval (95% CI). Fold-changes in geometric mean titer are shown above. P values were calculated using the Wilcoxon matched-pairs signed-rank test.
See this image and copyright information in PMC

References

    1. Zeng, G. et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis.10.1016/S1473-3099(21)00681-2 (2021). - PMC - PubMed
    1. Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv, 10.1101/2021.11.11.21266068 (2021).
    1. Cao, Y. et al. Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivatedvaccine. Cell Res. 32, 107–109 (2021). - PMC - PubMed
    1. Ai, J. et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern. Cell Res. 32, 103–106 (2021). - PMC - PubMed
    1. Falsey AR, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N. Engl. J. Med. 2021;385:1627–1629. doi: 10.1056/NEJMc2113468. - DOI - PMC - PubMed